Trial Profile
Clinical trial of Ampligen for use as a prophylactic/early-onset therapeutic against COVID-19.
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 31 Mar 2020
Price :
$35
*
At a glance
- Drugs Rintatolimod (Primary) ; Rintatolimod (Primary) ; Rintatolimod (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
- 26 Mar 2020 According to an AIM ImmunoTech media release, the company engaged ChinaGoAbroad (CGA) to facilitate pre-clinical and clinical trials of Ampligen in the People's Republic of China (PRC).
- 26 Mar 2020 According to an AIM ImmunoTech media release, the company intends, as a next step, to as rapidly as possible seek Institutional Review Board approvals and governmental authorizations to commence the clinical trials of Ampligen.
- 26 Mar 2020 According to an AIM ImmunoTech media release, the company is targeting the United States, Europe, Asia and Argentina for its clinical trials and, as necessary steps before clinical trials could begin, the company is in the process of soliciting one or more sites and qualified principal investigators in one or more countries. Protocols for potential clinical trial are in the final stages of development.